StockNews.com initiated coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Free Report) in a research report report published on Sunday morning. The firm issued a sell rating on the biopharmaceutical company’s stock.
Akari Therapeutics Price Performance
NASDAQ:AKTX opened at $2.26 on Friday. Akari Therapeutics has a 12 month low of $1.08 and a 12 month high of $4.40. The business’s 50-day moving average is $2.84 and its two-hundred day moving average is $2.84.
Akari Therapeutics Company Profile
Further Reading
- Five stocks we like better than Akari Therapeutics
- What Do S&P 500 Stocks Tell Investors About the Market?
- Home Depot Stock: Targeting 12% in 2024 and 25% More in 2025
- What is the S&P 500 and How It is Distinct from Other Indexes
- Is Tesla’s Valuation a Bubble or Backed by Real Growth?
- How to Most Effectively Use the MarketBeat Earnings Screener
- Trucking Stocks Led the Pack Last Week: Can They Keep Rolling?
Receive News & Ratings for Akari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.